{"id":58042,"date":"2024-11-28T08:39:24","date_gmt":"2024-11-28T08:39:24","guid":{"rendered":"https:\/?p=58042"},"modified":"2024-11-28T08:39:24","modified_gmt":"2024-11-28T08:39:24","slug":"mdwd-q3-earnings-analysis","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/","title":{"rendered":"MediWound Ltd (MDWD) Q3 2024 Earnings: Key Highlights and Future Prospects"},"content":{"rendered":"<p data-pm-slice=\"1 1 []\"><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/MDWD\">MediWound Ltd (MDWD)<\/a> has recently unveiled its financial results for the third quarter of 2024.\u00a0 The company has made significant advancements in its strategic objectives, marked by pivotal milestones, including FDA approval for pediatric use of NexoBrid.<\/p>\n<p data-pm-slice=\"1 1 []\">Is now the time to buy MDWD? Access our <a href=\"https:\/\/www.stocktargetadvisor.com\/detail_page_report\/Report?symbolstring=MDWD&amp;symbolstringinput=MDWD,QQQ&amp;endDate=undefined&amp;startDate=undefined&amp;hige=1&amp;score=33\">full analysis report here<\/a>, it\u2019s free.<\/p>\n<h2>Key Insights from MediWound&#8217;s Q3 Earning Report:<\/h2>\n<p>MediWound reported a quarterly revenue of $4.4 million, a decline from $4.8 million in Q3 2023, attributed primarily to reduced BARDA development service revenues. Despite the drop, NexoBrid&#8217;s product revenue met expectations, signaling strong market demand. However, higher R&amp;D and SG&amp;A expenses led to an operating loss of $5.1 million and a net loss of $10.3 million for the quarter.<\/p>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/pricing\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-58044 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2024\/11\/STA-Promotion-Banner-1.png\" alt=\"\" width=\"1333\" height=\"200\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/STA-Promotion-Banner-1.png 1333w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/STA-Promotion-Banner-1-300x45.png 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/STA-Promotion-Banner-1-1024x154.png 1024w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/STA-Promotion-Banner-1-150x23.png 150w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/STA-Promotion-Banner-1-768x115.png 768w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/STA-Promotion-Banner-1-1200x180.png 1200w\" sizes=\"(max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 1362px) 62vw, 840px\" \/><\/a><\/p>\n<h3>Operational Highlights:<\/h3>\n<ul data-spread=\"false\">\n<li><strong>FDA Approval of NexoBrid for Pediatric Use:<\/strong> This milestone enhances NexoBrid&#8217;s market reach across age groups in the U.S., aligning with approvals in the EU and Japan.<\/li>\n<li><strong>EscharEx Clinical Progress:<\/strong> The company is set to commence a Phase 3 trial for EscharEx, targeting venous leg ulcers, with an IND submission expected by year-end. A head-to-head Phase 2 study against collagenase is planned for 2025.<\/li>\n<\/ul>\n<p>Explore related <a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/MDWD\/etfs\" target=\"_new\" rel=\"noopener\">ETF<\/a> options to evaluate diverse investment strategies linked to MediWound!<\/p>\n<h2>Management Discussion and Analysis:<\/h2>\n<p>CEO Ofer Gonen emphasized MediWound\u2019s commitment to addressing unmet medical needs, particularly through innovations like EscharEx, which targets a $2 billion market for chronic wounds. The FDA\u2019s recognition of enzymatic debridement as a validated treatment bolsters NexoBrid&#8217;s role in emergency preparedness and strategic stockpiling initiatives.<\/p>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/widgets\"><img decoding=\"async\" class=\"aligncenter wp-image-58045 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2024\/11\/sta-stock-chart-widget-2024-11-28T132647.712.png\" alt=\"\" width=\"494\" height=\"593\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/sta-stock-chart-widget-2024-11-28T132647.712.png 494w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/sta-stock-chart-widget-2024-11-28T132647.712-250x300.png 250w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/sta-stock-chart-widget-2024-11-28T132647.712-125x150.png 125w\" sizes=\"(max-width: 494px) 85vw, 494px\" \/><\/a><\/p>\n<h2>Stock Target Advisor\u2019s Analysis on MediWound Ltd<\/h2>\n<p>According to <a href=\"https:\/\/www.stocktargetadvisor.com\/\">Stock Target Advisor<\/a>, MediWound Ltd\u2019s stock is rated &#8220;Slightly Bearish&#8221; based on three positive and six negative signals. Despite its &#8220;Strong Buy&#8221; analyst consensus rating, MediWound\u2019s high valuation ratios and negative cash flows have raised concerns.<\/p>\n<p>MediWound Ltd is currently covered by three analysts, <a href=\"https:\/\/www.stocktargetadvisor.com\/Analyst-Ranking\/H.C.-Wainwright\">with H.C. Wainwright<\/a> as the major name. Stock Target Advisor\u2019s 12-month target price for MediWound Ltd is $27.25, reflecting a potential 56.16% upside from its current price of $17.45.<\/p>\n<h2>Conclusion:<\/h2>\n<p>MediWound\u2019s Q3 2024 results encapsulate a transformative period for the company, marked by regulatory milestones, strategic clinical initiatives, and robust funding efforts.\u00a0 For a comprehensive view of MediWound\u2019s stock performance, explore Stock Target Advisor\u2019s insights to make informed investment decisions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MediWound Ltd (MDWD) has recently unveiled its financial results for the third quarter of 2024.\u00a0 The company has made significant advancements in its strategic objectives,&#8230;<\/p>\n","protected":false},"author":17,"featured_media":58046,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-58042","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MediWound Ltd (MDWD) Q3 2024 Earnings: Key Highlights and Future Prospects<\/title>\n<meta name=\"description\" content=\"MediWound&#039;s Q3 2024 results reveal growth opportunities with FDA approvals and manufacturing expansions\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MediWound Ltd (MDWD) Q3 2024 Earnings: Key Highlights and Future Prospects\" \/>\n<meta property=\"og:description\" content=\"MediWound&#039;s Q3 2024 results reveal growth opportunities with FDA approvals and manufacturing expansions\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-28T08:39:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/STAs-Blog-Images-2024-11-28T133842.376.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"MediWound Ltd (MDWD) Q3 2024 Earnings: Key Highlights and Future Prospects\",\"datePublished\":\"2024-11-28T08:39:24+00:00\",\"dateModified\":\"2024-11-28T08:39:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/\"},\"wordCount\":381,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/\",\"name\":\"MediWound Ltd (MDWD) Q3 2024 Earnings: Key Highlights and Future Prospects\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-11-28T08:39:24+00:00\",\"dateModified\":\"2024-11-28T08:39:24+00:00\",\"description\":\"MediWound's Q3 2024 results reveal growth opportunities with FDA approvals and manufacturing expansions\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MediWound Ltd (MDWD) Q3 2024 Earnings: Key Highlights and Future Prospects\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MediWound Ltd (MDWD) Q3 2024 Earnings: Key Highlights and Future Prospects","description":"MediWound's Q3 2024 results reveal growth opportunities with FDA approvals and manufacturing expansions","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/","og_locale":"en_US","og_type":"article","og_title":"MediWound Ltd (MDWD) Q3 2024 Earnings: Key Highlights and Future Prospects","og_description":"MediWound's Q3 2024 results reveal growth opportunities with FDA approvals and manufacturing expansions","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-11-28T08:39:24+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/STAs-Blog-Images-2024-11-28T133842.376.png","type":"image\/png"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"MediWound Ltd (MDWD) Q3 2024 Earnings: Key Highlights and Future Prospects","datePublished":"2024-11-28T08:39:24+00:00","dateModified":"2024-11-28T08:39:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/"},"wordCount":381,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/","name":"MediWound Ltd (MDWD) Q3 2024 Earnings: Key Highlights and Future Prospects","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-11-28T08:39:24+00:00","dateModified":"2024-11-28T08:39:24+00:00","description":"MediWound's Q3 2024 results reveal growth opportunities with FDA approvals and manufacturing expansions","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/mdwd-q3-earnings-analysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"MediWound Ltd (MDWD) Q3 2024 Earnings: Key Highlights and Future Prospects"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/58042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=58042"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/58042\/revisions"}],"predecessor-version":[{"id":58047,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/58042\/revisions\/58047"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/58046"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=58042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=58042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=58042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}